Lemme
US$ 28.25
glp 1 alzheimer's GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in disease Glucagon-like peptide-1 medicines in neurological
Description
Recognizing this distinction can shift the approach from frustration to strategy and from not working to working well
Five years later, in 2025, it reached $65.2 billion a 166% increase, with a 45% surge in the final year alone (Pharmaceutical Technology, 2026)
Rising case numbers expand the patient base needing effective, easier treatments like oral GLP-1 therapies
There are grounds for concern that the GLP-1 class of drugs may induce asymptomatic pancreatitis and, over time in some individuals, induce pancreatic cancer
Clin Pharmacokinet 57(10):13131328
Disclaimer: Results may vary
